We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Questions Uneven Benefits Seen in Teva’s Asthma Candidate
FDA Questions Uneven Benefits Seen in Teva’s Asthma Candidate
Given safety risks and weaker evidence in some patients, the FDA says it is questioning whether positive findings reported for Teva’s asthma drug reslizumab are enough to warrant approval.